We recently compiled a list of the The 10 Worst-Performing Stocks on Monday. In this article, we are going to take a look at where Moderna Inc. (NASDAQ:MRNA) stands against the other stocks. Ten ...

The S&P 500 fell 0.8% on Monday, Feb. 3, as investors reacted to tariffs on major U.S. trading partners while awaiting key ...

The S&P 500 Index ( $SPX) ( SPY) today is down -0.95%, the Dow Jones Industrials Index ( $DOWI ) ( DIA) is down -0.51%, and the Nasdaq 100 Index ( $IUXX) ( QQQ) is down -1.12%. March E-mini S&P ...

Former Goldman Sachs Group Inc. banker Nick Giovanni is rejoining the investment bank as partner in the technology, media and ...

Goldman Sachs is bringing back Nick Giovanni, who spent more than 20 years at the Wall Street giant in a prior stint, ...

The strategy's relative factor exposures have decreased in recent years as Goldman Sachs bolstered risk management resources and placed greater emphasis on letting stock-picking drive performance.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

MSD and partner Moderna have started a late-stage trial of their personalised cancer vaccine V940 as a combination with MSD’s PD-1 inhibitor Keytruda for patients with non-small cell lung cancer ...

The trial compared Moderna's MRNA-4157/V940 vaccine given alongside Merck & Co's cancer immunotherapy Keytruda (pembrolizumab) to Keytruda alone in patients with the skin cancer melanoma.